ImClone Systems, Inc. received approval from the FDA for a second facility to manufacture Erbitux. This new 250,000-sq.-ft. multi-suite manufacturing facility, referred to as “BB50”, more than doubles the company’s total production capacity for Erbitux. “The FDA approval of BB50 represents the culmination of ImClone’s efforts over the last several years to establish this state-of-the-art facility. This now provides us with a great deal of strategic and operat...